NYC Healthcare News

Arthritis Foundation, Takeda launch Gout Living educational campaign

April 17, 2016

The researchers tested the ability of VB-201 to protect against the development of EAE. With a statistically significant difference between control and groups dosed with 0.04 and 0.4 mg/kg of VB-201, the data demonstrated that orally administered VB-201 prevented the development of EAE and inhibited the ability of adoptive T-cells to cause EAE. These data suggest that VB-201 and other oxidized phospholipids may play an anti-inflammatory role in CNS autoimmune diseases.

"We are excited by these results, which suggest that VB-201 may have potential to treat MS, a disease in serious need of treatment options," said Professor Dror Harats, M.D., chief executive officer of VBL. "We are currently evaluating VB-201 in a Phase 2 clinical trial to treat psoriasis, and it has also demonstrated anti-inflammatory activity in rheumatoid arthritis, inflammatory bowel disease and atherosclerosis. We believe that these published data both broaden the clinical utility of VB-201 and suggest its potential as a chronic therapeutic option in the future. The results of this study will continue to inform our clinical strategy and help advance our mission to create treatments for life-threatening diseases inadequately addressed by current therapies."

Source : VBL Therapeutics